

DESCRIPTION

Source	Human embryonic kidney cell, HEK293-derived Gln22-His458, with a C-terminal 6-His tag Accession # Q8N423
N-terminal Sequence Analysis	No results obtained. Gln22 inferred from enzymatic pyroglutamate treatment revealing Thr23
Structure / Form	Monomer
Predicted Molecular Mass	48 kDa

SPECIFICATIONS

SDS-PAGE	62-72 kDa, reducing conditions
Activity	Measured by its binding ability in a functional ELISA. When Recombinant Human LILRB2/CD85d/ILT4 is coated at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with a typical ED ₅₀ of 25-150 ng/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE with silver staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA

<p>Bioactivity</p> <p>When Recombinant Human LILRB2/CD85d/ILT4 (Catalog # 8429-T4) is coated onto a microplate at 2 µg/mL, Recombinant Human Angiopoietin-like 7 Protein (Catalog # 914-AN) binds with a typical ED₅₀ of 25-150 ng/mL.</p>	<p>SDS-PAGE</p> <p>1 µg/lane of Recombinant Human LILRB2/CD85d/ILT4 (Catalog # 8429-T4) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing bands at 69.9 and 66.8 kDa, respectively.</p>
--	--

BACKGROUND

The immunoglobulin-like transcript (ILT) molecules comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1, 2). ILT4, also known as CD85d, LIR-2, and LILRB2, is closely related to mouse PIR-B and is primarily expressed on monocytes, dendritic cells (DC), and neutrophils (3, 4). Mature human ILT4 consists of a 440 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain with 3 inhibitory immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64% aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5-9). It competes with CD8 α for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces tyrosine phosphorylation within its cytoplasmic ITIMs, association with SHP-1, and inhibition of stimulatory signaling (3, 6). ILT4 activation promotes the development of tolerogenic dendritic cells and the subsequent induction of regulatory T cells and CD4⁺ T cell anergy (10-12). Ligation of ILT4 on neutrophils further attenuates immune responses by inhibiting neutrophil phagocytic activity and production of reactive oxygen species (4). ILT4 also binds to multimeric Angiopoietin-like 2, and its ligation supports the expansion of hematopoietic stem cells from cord blood (13). In the brain, ILT4 and mouse PIR-B function as receptors for oligomeric Abeta (1-42) peptide (14).

References:

1. Suci-Foca, N. *et al.* (2005) *Int. Immunopharmacol.* **5**:7.
2. Hofmeister, V. and E.H. Weiss (2003) *Semin. Canc. Biol.* **13**:317.
3. Fanger, N.A. *et al.* (1998) *Eur. J. Immunol.* **28**:3423.
4. Baudhuin, J. *et al.* (2013) *Proc. Natl. Acad. Sci. USA* **110**:17957.
5. Borges, L. *et al.* (1997) *J. Immunol.* **159**:5192.
6. Colonna, M. *et al.* (1998) *J. Immunol.* **160**:3096.
7. Shiroishi, M. *et al.* (2003) *Proc. Natl. Acad. Sci. USA* **100**:8856.
8. Lepin, E.J.M. *et al.* (2000) *Eur. J. Immunol.* **30**:3552.
9. Allen, R.L. *et al.* (2001) *J. Immunol.* **167**:5543.
10. Chang, C.C. *et al.* (2002) *Nat. Immunol.* **3**:237.
11. Ristich, V. *et al.* (2005) *Eur. J. Immunol.* **35**:1133.
12. Gregori, S. *et al.* (2010) *Blood* **116**:935.
13. Deng, M. *et al.* (2014) *Blood* **124**:924.
14. Kim, T. *et al.* (2013) *Science* **341**:1399.